LBPMedicine(SH:688393)2022-04-28 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 120,089,759.96, representing a year-on-year increase of 20.68%[5] - The net profit attributable to shareholders decreased by 26.40% to CNY 19,624,115.78 compared to the same period last year[5] - Basic and diluted earnings per share were both CNY 0.21, down 27.59% from the same period last year[6] - In Q1 2022, the company's net profit was CNY 17,321,842.35, a decrease of 34% compared to CNY 26,233,758.61 in Q1 2021[19] - The company reported a total profit of CNY 20,986,803.66, down 33% from CNY 31,255,584.08 in the previous year[19] - The total comprehensive income for the period was CNY 17,321,842.35, reflecting a decrease from CNY 26,233,758.61 in the previous year[20] Research and Development - Research and development expenses totaled CNY 14,813,078.40, which is an increase of 143.97% year-on-year, accounting for 12.34% of operating revenue[6] - Research and development expenses increased significantly to CNY 14,813,078.40, compared to CNY 6,071,613.10 in Q1 2021, marking a 144% rise[19] - Research and development expenses increased significantly to CNY 11,278,702.55, up 180.5% from CNY 4,024,853.55 in the same period last year[30] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 142,227.31, reflecting a significant decrease of 90.91% compared to the previous year[6] - The cash flow from operating activities showed a net increase of CNY 142,227.31, a decline from CNY 1,564,154.14 in Q1 2021[23] - The company's cash and cash equivalents at the end of the period totaled CNY 310,322,384.54, down from CNY 662,991,698.93 at the end of Q1 2021[24] - The net cash flow from operating activities in Q1 2022 was -¥3,572,285.51, compared to a positive net cash flow of ¥426,769.10 in Q1 2021, indicating a significant decline[33] - The company's cash and cash equivalents at the end of Q1 2022 stood at ¥290,606,781.98, compared to ¥644,469,476.43 at the end of Q1 2021, reflecting a decrease of approximately 55.1%[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,374,585,523.28, a slight increase of 0.65% from the end of the previous year[6] - Total assets as of March 31, 2022, were RMB 1,374,585,523.28, slightly up from RMB 1,365,683,854.03 at the end of 2021[16] - Total liabilities decreased to RMB 146,288,394.23 from RMB 155,959,139.08 at the end of 2021, a reduction of 6.5%[17] - The total liabilities increased to CNY 188,998,204.29 from CNY 183,613,066.30 at the end of 2021[28] - The company's equity attributable to shareholders increased to RMB 1,223,626,796.20 from RMB 1,204,002,680.42, reflecting a growth of 1.6%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,394[9] - The largest shareholder, Cai Xiangting, holds 21.23% of the shares, totaling 19,817,000 shares[10] Market and Strategic Developments - The company has not disclosed any new product developments or market expansion strategies in the current report[13] - There are no significant mergers or acquisitions reported during the quarter[13] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30]